冠心病合并重度高脂血症应用阿托伐他汀联合烟酸治疗的效果  

The Effect of Atorvastatin Combined With Niacin in the Treatment of Coronary Heart Disease With Severe Hyperlipidemia

作　　者：郑重[1] 梁燕[1] ZHENG Zhong;LIANG Yan(Department of Cardiology,Chongqing Three Gorges Central Hospital,Chongqing 404000,China)

机构地区：[1]重庆三峡中心医院心内科,重庆404000

出　　处：《中国继续医学教育》2020年第32期165-168,共4页China Continuing Medical Education

摘　　要：目的分析冠心病合并重度高脂血症患者应用阿托伐他汀联合烟酸缓释片治疗的临床价值及安全性。方法以本院2016年1月-2018年1月收治的68例冠心病合并重度高脂血症患者作为研究对象,采用双盲随机抽样法分为对照组和实验组,每组34例,对照组应用阿托伐他汀单药治疗,实验组阿托伐他汀联合烟酸缓释片治疗,评定两组患者的临床效果、心绞痛发作频率、血脂控制指标、不良反应及血脂控制达标率。结果实验组相较于对照组患者的心绞痛发作频率减少,血脂指标改善显著;实验组的临床效果(97.05%)相较于对照组(76.47%)高,差异有统计学意义(P<0.05);实验组患者的不良反应发生率(2.94%)与对照组(5.88%)比较,差异无统计学意义(P>0.05);实验组患者的血脂控制达标率(97.05%)较于对照组(73.52%)高,差异有统计学意义(P<0.05)。结论冠心病合并重度高脂血症患者采用阿托伐他汀联合烟酸缓释片治疗优势较为明显。Objective To analyze the clinical value and safety of atorvastatin combined with niacin sustainedrelease tablets in patients with coronary heart disease and severe hyperlipidemia.Methods A total of 68 patients with coronary heart disease and severe hyperlipidemia admitted to our hospital from January 2016 to January 2018 were selected as the research object.They were divided into the control group and the experimental group by double-blind random sampling method,with 34 cases in each group.The group was treated with atorvastatin as a single agent,and the experimental group was treated with atorvastatin combined with niacin sustained-release tablets.The clinical effects,frequency of angina pectoris,blood lipid control indicators,adverse reactions and blood lipid control attainment rates were evaluated.Results Compared with the control group,the experimental group had a reduced frequency of angina pectoris and improved blood lipid indexes.The clinical effect of the experimental group(97.05%)was higher than that of the control group(76.47%),and the difference was statistically significant(P<0.05);Compared with the control group(5.88%),the adverse reaction rate of the experimental group of patients(2.94%)was not statistically significant(P>0.05);the blood lipid control rate of the experimental group(97.05%)was higher than that of the control group(73.52%)high,the difference was statistically significant(P<0.05).Conclusion Patients with coronary heart disease and severe hyperlipidemia have obvious advantages in the treatment of atorvastatin combined with niacin sustained-release tablets.

关 键 词：冠心病 重度高脂血症 阿托伐他汀 烟酸缓释片 临床价值 安全性 

分 类 号：R972[医药卫生—药品]